GOG-209 — Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)

Phase 3 · 2012 · Endometrial Cancer

Design

Randomized, open-label, noninferiority phase III trial comparing carboplatin/paclitaxel (TC) with paclitaxel/doxorubicin/cisplatin (TAP) in advanced or recurrent endometrial cancer.

Population

Women with stage III, stage IV, or recurrent endometrial carcinoma with performance status 0-2 and no prior chemotherapy.

Primary Endpoint

Overall survival (noninferiority)

Key Result

TC was noninferior to TAP for overall survival (median 37 vs 41 months; HR 1.002, 90% CI 0.90-1.12) and PFS (median 13 vs 14 months; HR 1.032) with less toxicity.

Guideline Impact

Made carboplatin/paclitaxel the guideline-endorsed first-line standard for advanced/recurrent endometrial cancer